Pharmaceutical formulation for extended release

Details Pharmaceutical formulation for extended release Pharmaceutical formulation for extended release

A - Human Necessities

61

K

A61K 9/20 (2006.01) A61K 9/50 (2006.01)

Patent

CA 2696870

An extended release pharmaceutical formulation comprising, as active ingredient, the compound Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) or a pharmaceutically acceptable salt thereof (such as a sulfonic acid salt, such as the benzenesulfonic acid 5 (besylate) salt); and a pharmaceutically acceptable diluent or carrier; for use in providing a therapeutic anti-thrombotic effect whilst limiting drug-drug interactions with other concomitantly dosed drug/s, particularly those which are metabolised by CYP-450 enzymes.

L'invention concerne une formulation pharmaceutique à libération prolongée qui comprend comme principe actif le composé Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe), ou un sel pharmaceutiquement acceptable de ce composé (p. ex. sel d'acide sulfonique tel que le sel d'acide benzène sulfonique (bésylate)); et un diluant ou un excipient pharmaceutiquement acceptable; ladite formulation est destinée à produire un effet antithrombotique tout en limitant les interactions médicament-médicament avec un ou plusieurs autres médicament(s) administré(s) de manière concomitante, en particulier ceux qui sont métabolisés par les enzymes CYP-450.

Affiliated with

Also associated with

Rating

Pharmaceutical formulation for extended release does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical formulation for extended release, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulation for extended release will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1954359